Gilead Sciences stock weighs HIV growth against a Q2 EPS loss

Published on 10/06/2026 at 17:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Gilead Sciences stock traded at USD 144.43 on Nasdaq on October 6, 2026, while Q2 HIV sales rose 12 percent to USD 5.7 billion. Management lifted full-year HIV growth guidance to 9 percent to 10 percent.

Flatlay mit Aktienzertifikat ISIN US3755581036 Gilead Sciences Labormaterialien auf Marmor — Gilead Sciences Flatlay ISIN US3755581036 Aktienzertifikat ISIN-Karte Ampullen Molekülmodell Stethoskop weißer Marmor, Illustration mit AI erstellt.

Gilead Sciences stock stood at USD 144.43 on Nasdaq at 11:20 a.m. ET on October 6, 2026, with a daily change of -0.14 percent and a market capitalization of USD 179.1 billion. The investment case now balances 12 percent HIV growth in Q2 2026 against a non-GAAP diluted loss of USD 6.75 per share.

HIV growth leads the quarter

According to Fortune on August 4, 2026, Gilead reported Q2 HIV sales of USD 5.7 billion, up 12 percent from the prior-year quarter. Total product sales reached USD 7.6 billion, an 8 percent year-over-year increase.

The commercial picture was stronger than the headline earnings figure. PrEP sales exceeded USD 1 billion for the first time, while Biktarvy sales reached USD 3.8 billion, up 7 percent year over year, according to Fortune.

Guidance shifts toward HIV

Management raised full-year 2026 HIV sales growth guidance to 9 percent to 10 percent from 8 percent previously. The same call put the PrEP business at a USD 4 billion annual run rate and described Yeztugo sales of USD 232 million in Q2, up 40 percent sequentially.

Gilead also set a full-year base-business sales range of USD 29.8 billion to USD 30.1 billion and total product sales guidance of USD 30.1 billion to USD 30.4 billion, according to Fortune. The counter-factor is the accounting burden from acquisitions, which pushed reported Q2 earnings sharply below the underlying operating performance.

Analysts keep targets above Nasdaq quote

According to MarketBeat on October 5, 2026, 23 analysts rated Gilead Buy and six rated it Hold, producing a Moderate Buy consensus and an average target of USD 158.78. That target lies 9.94 percent above the USD 144.43 quote.

MarketBeat also reported that Zacks Research cut its rating from Strong Buy to Hold on September 29, 2026. The split between a positive aggregate view and a more cautious named action makes the October 22 reporting date a key checkpoint for the growth thesis.

Stock remains below yearly high

Gilead Sciences stock was USD 12.86 below its 52-week high of USD 157.29 and USD 31.61 above its 52-week low of USD 112.82 on October 6, 2026. The current quote therefore sits closer to the upper end of its yearly range than to the low, despite the small intraday decline.